Tempest Therapeutics, Inc.
Tempest Therapeutics is a clinical-stage biotechnology company developing cell therapy and small-molecule product candidates for cancer and other indications. Its cell therapy pipeline includes autologous, allogeneic and in vivo dual-targeting CAR-T candidates, including TPST-2003 for relapsed or refractory multiple myeloma, TPST-2206 and TPST-3206 for renal cell carcinoma, TPST-3003 for multiple myeloma, and TPST-4003 for lupus. Its small-molecule candidates are amezalpat, an oral PPARα antagonist being developed for first-line hepatocellular carcinoma, and TPST-1495, an oral EP2/EP4 antagonist being developed for familial adenomatous polyposis. Tempest advances candidates through clinical development and uses licenses, strategic partners and external funding to support development programs. Novatim funds clinical studies of TPST-2003 and supports development of other CAR-T programs. The National Cancer Institute is expected to fund the TPST-1495 Phase 2 study. Tempest is headquartered in Brisbane, California.
No SEC Form 4 filings for $TPST in the last 30 days.
See all $TPST insider activity →Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903 Secured access to additional ca
Tempest Therapeutics reported Q3 GAAP EPS of -$0.21, beating estimates by $0.11. The company had $0.9 million in cash and equivalents, down from $7.7 million at year-end 2025.
Tempest Therapeutics (TPST) licensed Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, following Phase 1 results of TPST-4903. The company secured up to $50M through an equity line and $2.5M in private-placement proceeds. Further clinical data and development plans will be key for investors.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning TPST (Tempest Therapeutics, Inc.). Coverage has been balanced: 2 bullish, 2 neutral, and 2 bearish.
Recent TPST coverage spans corporate actions, earnings and financial news.
The filing reveals weak cash position and dilution from recent financing, suggesting near‑term downside pressure, while the exclusive license to Senlang's CAR‑T platform offers a modest catalyst.
The beat is modest and the company remains loss-making, likely limiting upside.
The financing and platform license provide new cash and technology assets, likely supporting near‑term upside.
The licensing deal expands Tempest's pipeline and the preliminary clinical responses are encouraging, likely prompting buying interest.
The voting outcomes are routine corporate governance items with limited market effect.
AlphAI scores every news story that mentions TPST with an AI model for sentiment and relevance, and aggregates insider trades from Tempest Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903 Secured access to additional ca
Tempest Therapeutics reported Q3 GAAP EPS of -$0.21, beating estimates by $0.11. The company had $0.9 million in cash and equivalents, down from $7.7 million at year-end 2025.
Tempest Therapeutics (TPST) licensed Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, following Phase 1 results of TPST-4903. The company secured up to $50M through an equity line and $2.5M in private-placement proceeds. Further clinical data and development plans will be key for investors.
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate -Tempest secures exclusive global rights outside China to a targeted lentiviral platform and po
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On November 9, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”). The final results for each of the proposals submitted to
Tempest Therapeutics (TPST) received a notice from Nasdaq on November 4, 2026, for its stock closing below $1.00 for 30 days, violating Listing Rule 5550(a)(2). The company has until May 3, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 days. The notice does not immediately affect its Nasdaq listing.
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer and Principal Financial and Accounting Officer On October 26, 2026, Ms. Constance Ame
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. Item 8.01. Other Events. On October 14, 2026, Tempest Therapeutics, Inc. (the “Company”) called to order
Tempest Therapeutics (TPST) appointed John Frederick, a 62-year-old retired executive with 30+ years of experience, as a Class III director effective October 13, 2026. Frederick previously served as CFO and Chief Transformation Officer at Skillsoft and held leadership roles at Indigo Ag and SumTotal.
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise Brisbane, CA , October 14, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T th
